Updated national and international hypertension guidelines: a review of current recommendations

Sverre Kjeldsen, Ross D Feldman, Liu Lisheng, Jean-Jacques Mourad, Chern-En Chiang, Weizhong Zhang, Zhaosu Wu, Wei Li, Bryan Williams, Sverre Kjeldsen, Ross D Feldman, Liu Lisheng, Jean-Jacques Mourad, Chern-En Chiang, Weizhong Zhang, Zhaosu Wu, Wei Li, Bryan Williams

Abstract

Despite the availability of effective pharmacological treatments to aid the control of blood pressure, the global rate of uncontrolled blood pressure remains high. As such, further measures are required to improve blood pressure control. Recently, several national and international guidelines for the management of hypertension have been published. These aim to provide easily accessible information for healthcare professionals and patients to aid the diagnosis and treatment of hypertension. In this review, we have compared new and current guidelines from the American and International Societies of Hypertension; the American Heart Association, American College of Cardiology and the US Center for Disease Control and Prevention; the panel appointed to the Eighth Joint National Committee; the European Societies of Hypertension and Cardiology; the French Society of Hypertension; the Canadian Hypertension Education Program; the National Institute for Health and Clinical Excellence (UK); the Taiwan Society of Cardiology and the Chinese Hypertension League. We have identified consensus opinion regarding best practises for the management of hypertension and have highlighted any discrepancies between the recommendations. In general there is good agreement between the guidelines, however, in some areas, such as target blood pressure ranges for the elderly, further trials are required to provide sufficient high-quality evidence to form the basis of recommendations.

References

    1. World Health Organisation. A global brief on hypertension: silent killer, global public health crisis. 2013. . Accessed 19 June 2014.
    1. He FJ, MacGregor GA. Cost of poor blood pressure control in the UK: 62000 unnecessary deaths per year. J Hum Hypertens. 2003;17:455–457. doi: 10.1038/sj.jhh.1001581.
    1. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8) JAMA. 2014;311:507–520. doi: 10.1001/jama.2013.284427.
    1. Go AS, Bauman M, King SMC, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878–885. doi: 10.1161/HYP.0000000000000003.
    1. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3–15. doi: 10.1097/HJH.0000000000000065.
    1. Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program (CHEP) recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention and treatment of hypertension. Can J Cardiol. 2014;30:485–501. doi: 10.1016/j.cjca.2014.02.002.
    1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J. 2013;34:2159–2219. doi: 10.1093/eurheartj/eht151.
    1. National Institute for Health and Care Excellence. Hypertension: clinical management of primary hypertension in adults (Clinical guideline 127). . Accessed 19 June 2014.
    1. Blacher J, Halimi JM, Hanon O, et al. Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol. 2014;28:1–9. doi: 10.1111/fcp.12044.
    1. Chiang C-E, Wang T-D, Li Y-H, et al. 2010 Guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc. 2010;109:740–773. doi: 10.1016/S0929-6646(10)60120-9.
    1. Liu LS. 2010 Chinese guidelines for the management of hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39:579–615.
    1. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011;378:1219–1230. doi: 10.1016/S0140-6736(11)61184-7.
    1. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–1898. doi: 10.1056/NEJMoa0801369.
    1. Wright JT, Jr, Fine LJ, Lackland DT, et al. Evidence supporting a systolic blood pressure goal of less than 150 mmHg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014;160:499–503. doi: 10.7326/M13-2981.
    1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J. 2007;28:1462–1536.
    1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2.
    1. ACCORD Study Group Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–1585. doi: 10.1056/NEJMoa1001286.
    1. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762. doi: 10.1016/S0140-6736(98)04311-6.
    1. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713. doi: 10.1136/bmj.317.7160.703.
    1. Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799–2810. doi: 10.1161/CIRCULATIONAHA.110.016337.
    1. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. TIght blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–68. doi: 10.1001/jama.2010.884.
    1. Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;29:1253–1269. doi: 10.1097/HJH.0b013e3283469976.
    1. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009:CD004349.
    1. Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541–548. doi: 10.7326/0003-4819-154-8-201104190-00335.
    1. Appel LJ, Wright JT, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918–929. doi: 10.1056/NEJMoa0910975.
    1. Eckel RH, Jakicic JM, Ard JD, et al. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129:25(Suppl. 2):S76–99.
    1. Simplicity HTN-1 Investigators Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–917. doi: 10.1161/HYPERTENSIONAHA.110.163014.
    1. Institute of Medicine. Sodium intake in populations. Assessment of evidence. 2013. . Accessed 5 Sept 2014.
    1. Graudal N, Jürgens G, Baslund B, et al. Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. Am J Hypertens. 2014;27:1129–1137. doi: 10.1093/ajh/hpu028.
    1. MRC Working Party Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405–412. doi: 10.1136/bmj.304.6824.405.
    1. Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012:CD002003.
    1. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–2236. doi: 10.1001/jama.292.18.2227.
    1. Manrique C, Giles TD, Ferdinand KC, et al. Realities of newer β-blockers for the management of hypertension. J Clin Hypertens. 2009;11:369–375. doi: 10.1111/j.1751-7176.2009.00140.x.
    1. Bonet S, Agustí A, Arnau JM, et al. Β-adrenergic blocking agents in heart failure: benefits of vasodilating and nonvasodilating agents according to patients’ characteristics: a meta-analysis of clinical trials. Arch Intern Med. 2000;160:621–627. doi: 10.1001/archinte.160.5.621.
    1. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53:646–653. doi: 10.1161/HYPERTENSIONAHA.108.123455.
    1. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310:699–705. doi: 10.1001/jama.2013.108769.
    1. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290–300. doi: 10.1016/j.amjmed.2008.09.038.
    1. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28:1587–1590. doi: 10.1097/HJH.0b013e328339f9fa.
    1. ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559. doi: 10.1056/NEJMoa0801317.
    1. Parving H-H, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–2213. doi: 10.1056/NEJMoa1208799.
    1. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399–407. doi: 10.1161/HYPERTENSIONAHA.109.139816.
    1. Kjeldsen SE, Messerli FH, Chiang C-E, et al. Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin. 2012;28:1685–1697. doi: 10.1185/03007995.2012.729505.
    1. Dickson M, Plauschinat CA. Racial differences in medication compliance and healthcare utilization among hypertensive medicaid recipients: fixed-dose vs free-combination treatment. Ethn Dis. 2008;18:204–209.
    1. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008;8:45–50. doi: 10.2165/00129784-200808010-00006.
    1. The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) JAMA. 2002;288:2981–2997. doi: 10.1001/jama.288.23.2981.
    1. Leenen FHH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48:374–384. doi: 10.1161/.
    1. National Institute of Clinical Excellance. Hypertension in pregnancy, guideline 107. 2010. Accessed 5 Sept 2014.
    1. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;19:b1665. doi: 10.1136/bmj.b1665.
    1. Esler MD, Krum H, Schlaich M, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the symplicity htn-2 randomized, controlled trial. Circulation. 2012;126:2976–2982. doi: 10.1161/CIRCULATIONAHA.112.130880.
    1. Symplicity HTN-2 Investigators. Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–1909. doi: 10.1016/S0140-6736(10)62039-9.
    1. Shimamoto K, Ando K, Fukita T, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014) Hypertens Res. 2014;37(4):253–387. doi: 10.1038/hr.2014.20.
    1. Knott C, Mindell J. Health Survey for England: 2011. 2011. . Accessed 19 June 2014.
    1. McAlister FA, Feldman RD, Wyard K, et al. The impact of the Canadian hypertension education programme in its first decade. Eur Heart J. 2009;30:1434–1439. doi: 10.1093/eurheartj/ehp192.
    1. Peterson ED, Gaziano J, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes? JAMA. 2013;311:474–476. doi: 10.1001/jama.2013.284430.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera